Portmanteau inhibitor

A portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV reverse transcriptase inhibitor and an integrase inhibitor,[1][2][3] and was further used in 2011 by a team of researchers combining an integrase inhibitor with a CCR5 entry inhibitor.[4]

Footnotes

  1. ↑ "U of M researchers announce advance in treatment of HIV". 25 July 2007. Retrieved 25 July 2007.
  2. ↑ "Researchers Discover New Method To Combat HIV". 25 July 2007. Retrieved 25 July 2007.
  3. ↑ Zhengqiang Wang; Eric M. Bennett; Daniel J. Wilson; Christine Salomon; Robert Vince (2007). "Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase". Journal of Medicinal Chemistry. 50 (15): 3416–3419. CiteSeerX 10.1.1.535.8472. doi:10.1021/jm070512p. PMID 17608468.
  4. ↑ Bodiwala, H. S.; Sabde, S.; Gupta, P.; Mukherjee, R.; Kumar, R.; Garg, P.; Bhutani, K. K.; Mitra, D.; Singh, I. P. (2011). "Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5". Bioorganic & Medicinal Chemistry. 19 (3): 1256–63. doi:10.1016/j.bmc.2010.12.031. PMID 21227704.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.